论文部分内容阅读
目的观察雷珠单抗联合黄斑格栅光凝治疗糖尿病黄斑水肿的临床效果。方法糖尿病黄斑水肿患者70例(70只眼),按数字表法随机分为联合组和对照组,各35例。联合组采用先行雷珠单抗玻璃体腔内注射,1周后再行标准的黄斑区格栅状光凝;对照组则单纯行雷珠单抗玻璃体腔内注射治疗。比较两组治疗前后1、3、6个月的最佳矫正视力(BCVA)和黄斑中心视网膜厚度(CMT)的改变。结果治疗前两组的BCVA、CMT比较差异均无统计学意义(P>0.05)。治疗后两组1、3、6个月BCVA及CMT与治疗前比较差异均有统计学意义(P<0.05),两组1、3、6个月各对应时间点比较,联合组均优于对照组(P<0.05)。结论雷珠单抗玻璃体腔内注射联合黄斑格栅光凝治疗与单纯雷珠单抗玻璃体腔内注射治疗相比能提高视力,减轻黄斑水肿,能保证疗效更持久。
Objective To observe the clinical effect of ranibizumab combined with macular grid photocoagulation in the treatment of diabetic macular edema. Methods Seventy patients (70 eyes) with diabetic macular edema were randomly divided into combined group and control group according to the digital table method, with 35 cases in each group. The combined group received the first intravitreal injection of ranibizumab, and then the standard macular grid photocoagulation was performed one week later. The control group was treated with intravitreal injection of ranibizumab alone. The changes of best corrected visual acuity (BCVA) and macular center retinal thickness (CMT) in two groups before and after treatment were compared. Results There was no significant difference in BCVA and CMT between the two groups before treatment (P> 0.05). After treatment, the BCVA and CMT of 1, 3 and 6 months groups were significantly different from those before treatment (P <0.05), and the corresponding time points of 1, Control group (P <0.05). Conclusion Intravitreal injection of levizumab in combination with macular grid photocoagulation can improve visual acuity and reduce macular edema compared with simple intravitreal injection of ranibizumab, which can ensure a longer lasting effect.